Literature DB >> 28661518

Challenges in the development of bio-based solvents: a case study on methyl(2,2-dimethyl-1,3-dioxolan-4-yl)methyl carbonate as an alternative aprotic solvent.

Saimeng Jin1, Fergal Byrne, Con Robert McElroy, James Sherwood, James H Clark, Andrew J Hunt.   

Abstract

Many traditional solvents have drawbacks including sustainability and toxicity issues. Legislation, such as REACH, is driving the move towards less hazardous chemicals and production processes. Therefore, safer bio-based solvents need to be developed. Herein, a 10 step method has been proposed for the development of new bio-based solvents, which utilises a combination of in silico modelling of Hansen solubility parameters (HSPs), experimental Kamlet-Abboud-Taft parameters, a selection of green synthetic routes followed by application testing and toxicity measurements. The challenges that the chemical industry face in the development of new bio-based solvents are highlighted through a case study on methyl(2,2-dimethyl-1,3-dioxolan-4-yl)methyl carbonate (MMC), which can be synthesised from glycerol. Although MMC is an attractive candidate as a replacement solvent, simply being bio-derived is not enough for a molecule to be regarded as green. The methodology of solvent development described here is a broadly applicable protocol that will indicate if a new bio-based solvent is functionally proficient, and will also highlight the importance of early stage Kamlet-Abboud-Taft parameters determination and toxicity testing in the development of a green solvent.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28661518     DOI: 10.1039/c7fd00049a

Source DB:  PubMed          Journal:  Faraday Discuss        ISSN: 1359-6640            Impact factor:   4.008


  1 in total

1.  3-Methoxybutan-2-one as a sustainable bio-based alternative to chlorinated solvents.

Authors:  Saimeng Jin; Fergal P Byrne; James H Clark; Con Robert McElroy; Alex Quinn; James Sherwood; Andrew J Hunt
Journal:  RSC Adv       Date:  2021-12-10       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.